Jai S. Rudra

Jai S. Rudra

Auto-generated profile, based on publicly available information

Jai S. Rudra

Washington University in St. Louis

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
ZWZheyu Wang
Zheyu Wang
JLJingyi Luan
Jingyi Luan
ASAnushree Seth
Anushree Seth
LLLin Liu
Lin Liu
MYMinli You
Minli You
SSSrikanth Singamaneni
Srikanth Singamaneni

1 August 2013 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
GHGregory A. Hudalla
Gregory A. Hudalla
JMJustin A. Modica
Justin A. Modica
YTYe F. Tian
Ye F. Tian
JRJai S. Rudra
Jai S. Rudra
ACAnita S. Chong
Anita S. Chong
JCJoel H. Collier
Joel H. Collier
This work illustrates a strategy for the design of molecularly defined immunotherapies, using a blend of supramolecular peptide self‐assembly and active site‐directed protein capture.

27 April 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TCTara M. Clover
Tara M. Clover
COConor L. O’neill
Conor L. O’neill
RARajagopal Appavu
Rajagopal Appavu
GLGiriraj Lokhande
Giriraj Lokhande
AGAkhilesh K. Gaharwar
Akhilesh K. Gaharwar
JRJai S. Rudra
Jai S. Rudra

16 May 2021 in Acta Biomaterialia
Verified
Journal Article
Open access
COConor L. O'NEill
Conor L. O'NEill
PSParesh C. Shrimali
Paresh C. Shrimali
ZCZoe E. Clapacs
Zoe E. Clapacs
MFMegan A. Files
Megan A. Files
JRJai S. Rudra
Jai S. Rudra
Currently approved replication-competent and inactivated vaccines are limited by excessive reactogenicity and poor safety profiles, while subunit vaccines are often insufficiently immunogenic without co-administering exogenous adjuvants. Self-assembling peptide-, peptidomimetic-, and protein-based biomaterials offer a means to overcome these challenges through their inherent modularity, multivalency, and biocompatibility. As these scaffolds are biologically derived and present antigenic arrays reminiscent of natural viruses, they are prone to immune recognition and are uniquely capable of functioning as self-adjuvanting vaccine delivery vehicles that improve humoral and cellular responses. Beyond this intrinsic immunological advantage, the wide range of available amino acids allows for facile de novo design or straightforward modifications to existing sequences. This has permitted the development of vaccines and immunotherapies tailored to specific disease models, as well as generalizable platforms that have been successfully applied to prevent or treat numerous infectious and non-infectious diseases. In this review, we briefly introduce the immune system, discuss the structural determinants of coiled coils, β-sheets, peptide amphiphiles, and protein subunit nanoparticles, and highlight the utility of these materials using notable examples of their innate and adaptive immunomodulatory capacity. STATEMENT OF SIGNIFICANCE: Subunit vaccines have recently gained considerable attention due to their favorable safety profiles relative to traditional whole-cell vaccines; however, their reduced efficacy requires co-administration of reactogenic adjuvants to boost immune responses. This has led to collaborative efforts between engineers and immunologists to develop nanomaterial-based vaccination platforms that can elicit protection without deleterious side effects. Self-assembling peptidic biomaterials are a particularly attractive approach to this problem, as their structure and function can be controlled through primary sequence design and their capacity for multivalent presentation of antigens grants them intrinsic self-adjuvanticity. This review introduces the various architectures adopted by self-assembling peptides and discusses their application as modulators of innate and adaptive immunity.

1 February 2014 in Vaccine
Verified
Journal Article
Closed access
CCCharles B. Chesson
Charles B. Chesson
EHErica J. Huelsmann
Erica J. Huelsmann
ALAndrew T. Lacek
Andrew T. Lacek
FKFrederick J. Kohlhapp
Frederick J. Kohlhapp
MWMatthew F. Webb
Matthew F. Webb
JRJai S. Rudra
Jai S. Rudra

19 May 2015 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
FKFrederick J Kohlhapp
Frederick J Kohlhapp
JBJoseph R Broucek
Joseph R Broucek
THTasha Hughes
Tasha Hughes
EHErica J Huelsmann
Erica J Huelsmann
JLJevgenijs Lusciks
Jevgenijs Lusciks
HKHoward Kaufman
Howard Kaufman
Background Melanoma is one of the few types of cancer with an increasing annual incidence. While a number of immunotherapies for melanoma have been associated with significant clinical benefit, including high-dose IL-2 and cytotoxic T lymphocyte antigen 4 (CTLA-4) blockade, clinical response to either of these single agents has been limited to 11-20% of treated patients. Therefore, in this study, we sought to test the hypothesis that the combination of IL-2 and CTLA-4 blockade could mediate a more profound therapeutic response. Methods Here, B6 mice were challenged with poorly immunogenic B16 melanoma on day 0, and treated with CTLA-4 blocking antibody (100 μg/mouse) on days 3, 6, and 9, and IL-2 (100,000 units) twice daily on days 4–8, or both. Results A highly significant synergistic effect that delayed tumor growth and prolonged survival was demonstrated with the combination immunotherapy compared to either monotherapy alone. The therapeutic effect of combination immunotherapy was dependent on both CD8+ T and NK cells and co-depletion of these subsets (but not either one alone) abrogated the therapeutic effect. CTLA-4 blockade increased immune cell infiltration (including CD8+ T cells and NK cells) in the tumor and IL-2 reduced the proportion of highly differentiated/exhausted tumor-infiltrating NK cells. Conclusions These results have implications for the design of clinical trials in patients with metastatic melanoma and provide new insights into how the immune system may be mediating anti-tumor activity with combination IL-2 and CTLA-4 blockade in melanoma.